医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Hoya Announces Third Quarter Financial Results

2015年01月30日 PM07:52
このエントリーをはてなブックマークに追加


 

TOKYO

Hoya Corporation (TOKYO:7741) today announced financial results for the third quarter ended December 31, 2014.

During the quarter, revenues increased 16.9% to 128,206 million yen, and profit before tax increased 22.9% to 36,240 million yen compared with the same quarter last year. Profit for the quarter was up 30.8% to 29,142 million yen, and profit attributable to owners of the company was up 40.1% year on year to 28,902 million yen.

In the Information Technology segment, sales of products related to smartphones and tablet PCs as well as glass disks for HDDs performed well, whereas sales continued to perform weakly in the products related to digital cameras. Revenues from eyeglass lenses grew substantially in the Life Care segment due to increased sales in overseas markets and through inclusion of a sales company of SEIKO eye wear as a consolidated subsidiary. The endoscope business performed well in Asia, and the retail contact lens business in Japan recovered to the previous year level and resulted in higher earnings for this quarter after experiencing a sales drop in the first quarter due to weak demand after the tax hike beginning in April.

For the nine months ended December 31, 2014, revenues were up 16.1% to 362,520 million yen and profit before tax was up 41.7% year on year to 92,940 million yen. Profit for the term was up 57.1% to 74,427 million yen, and profit attributable to owners of the company was up 61.7% to 73,851 million yen.

“Eyeglass business led the growth in Life Care segment gaining market share overseas,” said Hiroshi Suzuki, chief executive officer of HOYA. “We will further promote the business by enhancing resources and products. I am confident that the quality of our eyeglass lens is highly competitive.”

Eiichiro Ikeda, chief operation officer for Information Technology segment commented, “this quarter’s result, which exceeded our expectation, was outcome of swift restructuring measures we have taken in the past few years. To ensure future growth of Information Technology, we will be seeking new applications and directions.”

 

Summary of Consolidated Financial Statement

(Millions of Yen: Rounded to the nearest million)
  Three months ended   Variance   Nine months ended   Variance
  Dec. 2013   Dec. 2014   (%) Dec. 2013   Dec. 2014   (%)
Revenue 109,690   128,206 16.9 312,351   362,520 16.1
Profit before tax 29,499 36,240 22.9 65,594 92,940 41.7
Profit for the term 22,274 29,142 30.8 47,382 74,427 57.1
Profit attributable to owners of the company 20,633 28,902 40.1 45,663 73,851 61.7
Basic earnings per share(yen)   47.79   68.25       105.80   173.47    

Hoya also announced the projected results for the fiscal year ending March 31, 2015. Hoya forecasts revenues of 482.5 billion yen (up 12.8% compared to the previous year), profit before tax of 119 billion yen (up 39.2%) and profit for the term of 94 billion yen (up 56.3%).

About Hoya

Founded in 1941 in Japan, Hoya is a global med-tech company and a leading supplier of innovative high-tech and medical products. Hoya is active in the fields of Life Care and Information Technology providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses as well as key components for semiconductor devices, LCD panels and HDDs. Hoya currently employs over 34,500 people worldwide. For more information, please visit http://www.hoya.com.

CONTACT

Hoya Group
Akiko Chiba, +81-3-3952-6416
Public Relations
HOYA-pr@hoya.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表